CytomX Therapeutics Inc. has landed its second strategic bispecifics collaboration, this time with Astellas Pharma Inc. of Japan in a deal potentially worth more than $1.6bn that focuses on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens, for the treatment of cancer.
Under the deal, announced on 23 March, CytomX is eligible for high-single to mid-teen royalties, and may also exercise an...